Prostate cancer staging
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Prostate cancer staging is the process by which physicians evaluate the spread of prostate cancer. This is important because in a good cancer staging system, the stage of disease helps determine prognosis and assists in selecting therapies. A combination of physical examination, blood tests, and medical imaging is used to determine the clinical stage; if tissue is obtained via biopsy or surgery, examination of the tissue under a microscope can provide pathologic staging.
There are two schemes commonly used to stage prostate cancer. The most common is the TNM system, which evaluates the size of the tumor, the extent of involved lymph nodes, and any metastasis (distant spread). As with many other cancers, these are often grouped into four stages (I–IV). Another scheme, used less commonly, is the Whitmore-Jewett stage.
Briefly, Stage I disease is cancer that is found incidentally in a small part of the sample when prostate tissue was removed for other reasons, such as benign prostatic hypertrophy, and the cells closely resemble normal cells and the gland feels normal to the examining finger. In Stage II more of the prostate is involved and a lump can be felt within the gland. In Stage III, the tumor has spread through the prostatic capsule and the lump can be felt on the surface of the gland. In Stage IV disease, the tumor has invaded nearby structures, or has spread to lymph nodes or other organs. Grading is based on cellular content and tissue architecture from biopsies (Gleason) which provides an estimate of the destructive potential and ultimate prognosis of the disease.
TNM staging
From the AJCC 6th edition (2002) and UICC 6th edition.
Evaluation of the (primary) tumor ('T')
- TX: cannot evaluate the primary tumor
- T0: no evidence of tumor
- T1: tumor present, but not detectable clinically or with imaging
- T1a: tumor was incidentally found in less than 5% of prostate tissue resected (for other reasons)
- T1b: tumor was incidentally found in greater than 5% of prostate tissue resected
- T1c: tumor was found in a needle biopsy performed due to an elevated serum PSA
- T2: the tumor can be felt (palpated) on examination, but has not spread outside the prostate
- T2a: the tumor is in half or less than half of one of the prostate gland's two lobes
- T2b: the tumor is in more than half of one lobe, but not both
- T2c: the tumor is in both lobes
- T3: the tumor has spread through the prostatic capsule (if it is only part-way through, it is still T2)
- T3a: the tumor has spread through the capsule on one or both sides
- T3b: the tumor has invaded one or both seminal vesicles
- T4: the tumor has invaded other nearby structures
It should be stressed that the designation "T2c" implies a tumor which is palpable in both lobes of the prostate. Tumors which are found to be bilateral on biopsy only but which are not palpable bilaterally should not be staged as T2c.
Evaluation of the regional lymph nodes ('N')
- NX: cannot evaluate the regional lymph nodes
- N0: there has been no spread to the regional lymph nodes
- N1: there has been spread to the regional lymph nodes
Evaluation of distant metastasis ('M')
- MX: cannot evaluate distant metastasis
- M0: there is no distant metastasis
- M1: there is distant metastasis
- M1a: the cancer has spread to lymph nodes beyond the regional ones
- M1b: the cancer has spread to bone
- M1c: the cancer has spread to other sites (regardless of bone involvement)
Evaluation of the histologic grade ('G')
Usually, the grade of the cancer (how different the tissue is from normal tissue) is evaluated separately from the stage; however, for prostate cancer, grade information is used in conjunction with TNM status to group cases into four overall stages.
- GX: cannot assess grade
- G1: the tumor closely resembles normal tissue (Gleason 2–4)
- G2: the tumor somewhat resembles normal tissue (Gleason 5–6)
- G3–4: the tumor resembles normal tissue barely or not at all (Gleason 7–10)
Of note, this system of describing tumors as "well-", "moderately-", and "poorly-" differentiated based on Gleason score of 2-4, 5-6, and 7-10, respectively, persists in SEER and other databases but is generally outdated. In recent years pathologists rarely assign a tumor a grade less than 3, particularly in biopsy tissue. A more contemporary consideration of Gleason grade is:
- Gleason 3+3: tumor is low grade (favorable prognosis)
- Gleason 3+4 / 3+5: tumor is mostly low grade with some high grade
- Gleason 4+3 / 5+3: tumor is mostly high grade with some low grade
- Gleason 4+4 / 4+5 / 5+4 / 5+5: tumor is all high grade
Overall staging
The tumor, lymph node, metastasis, and grade status can be combined into four stages of worsening severity.
| Stage | Tumor | Nodes | Metastasis | Grade |
|---|---|---|---|---|
| Stage I | T1a | N0 | M0 | G1 |
| Stage II | T1a | N0 | M0 | G2–4 |
| T1b | N0 | M0 | Any G | |
| T1c | N0 | M0 | Any G | |
| T1 | N0 | M0 | Any G | |
| T2 | N0 | M0 | Any G | |
| Stage III | T3 | N0 | M0 | Any G |
| Stage IV | T4 | N0 | M0 | Any G |
| Any T | N1 | M0 | Any G | |
| Any T | Any N | M1 | Any G |
Whitmore-Jewett staging
The Whitmore-Jewett system is similar to the TNM system, with approximately equivalent stages. Roman numerals are sometimes used instead of Latin letters for the overall stages (for example, Stage I for Stage A, Stage II for Stage B, and so on).
- A: tumor is present, but not detectable clinically; found incidentally
- A1: tissue resembles normal cells; found in a few chips from one lobe
- A2: more extensive involvement
- B: the tumor can be felt on physical examination but has not spread outside the prostatic capsule
- BIN: the tumor can be felt, it does not occupy a whole lobe, and is surrounded by normal tissue
- B1: the tumor can be felt and it does not occupy a whole lobe
- B2: the tumor can be felt and it occupies a whole lobe or both lobes
- C: the tumor has extended through the capsule
- C1: the tumor has extended through the capsule but does not involve the seminal vesicles
- C2: the tumor involves the seminal vesicles
- D: the tumor has spread to other organs
Risk groups
While TNM staging is important, the TNM stage alone is not sufficient for deciding what treatment is best for a patient with prostate cancer. Instead, a different category called "risk groups" is used, which is based on the T-stage of the TNM system and adds additional information from the Gleason score and prostate specific antigen (PSA) value. The risk can be described as low risk, intermediate risk, or high risk. The risk is a useful predictor of having extraprostatic extension, which is spread of the cancer beyond the prostate gland itself. Although slightly different criteria are used for assigning risk, one such system defines low risk as a PSA less than 10, a Gleason score of 6 or lower, and a T-stage of T2a or lower; high risk is a PSA more than 20, a Gleason score of 8 or higher, or T2c; intermediate risk is a PSA of 10 to 20, T2b, or a Gleason of 7.
Patients with low risk disease may be treated with prostatectomy or radiotherapy alone. Patients with intermediate risk disease are usually treated with radiotherapy and a short duration (less than 6 months) of hormonal ablation (medical castration using a gonadotropin-releasing hormone analog), and those with high risk disease are usually treated with radiotherapy and a long duration of hormonal ablation.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
